CVS Health has opted to divide its businesses into two distinct companies, the source reported. One new company will hold the insurer Aetna and the pharmacy-benefit manager Caremark; the other will contain the company’s approximately 9,000 retail pharmacy locations. The split is planned for early 2028. This move reverses the structure created by the near-$70 billion merger that combined Aetna and CVS a decade ago. The article did not provide additional details about governance, leadership, tax considerations, or employee transitions tied to the separation.
Executives reportedly determined that two separate entities will better reflect their strategic priorities. The public text did not outline how liabilities, contracts, or partnerships will be allocated between the two companies. The market and regulatory approvals that may be required for the transaction were not described in the source material. Readers should therefore treat operational specifics and transitional arrangements as unresolved in the reporting provided.
Regulatory observers flagged a marked increase in the U.S. Food and Drug Administration’s use of unannounced foreign drug inspections in Fiscal Year 2026. The reported intent was to move toward inspection parity between domestic and international facilities, the article said. In India, the proportion of unannounced inspections rose from 47% in FY 2025 to 87% in FY 2026. In China, the comparable share climbed from 19% in FY 2025 to 61% in FY 2026.
The source attributed the increase to an agency effort to align inspection practices, but it did not provide a breakdown of the total number of inspections conducted, the specific facilities targeted, or the therapeutic categories involved. The piece also did not detail how these unannounced visits affected inspection outcomes, enforcement actions, or compliance trends at individual manufacturers. The reporting relied on regulatory summaries and secondary coverage; readers seeking full inspection logs or FDA internal rationale would need to consult primary agency releases or follow-up reports.
The statistics reported—percentage increases for unannounced visits—suggest a substantial operational shift. Short-term disruptions to supply chains or manufacturer operations could follow unannounced visits, depending on findings. That said, the source did not document any immediate production impacts, recalls, or enforcement letters tied to the FY 2026 inspection campaign.
Pharmaceutical firm Servier told the press that an experimental therapy it purchased for $1.55 billion in cash did not slow a rare form of muscular dystrophy in its first major test. The article presented this as a material development for the company’s pipeline. The source did not report trial size, primary or secondary endpoints, dosing regimens, statistical results, or safety findings. Nor did it include remarks from investigators, patient groups, or independent analysts about the failure.
Because those methodological and outcome details were absent from the public text, clinicians and researchers cannot assess the trial’s design quality, its target population, or whether subgroup analyses produced any signals that might justify additional study. The lack of such information limits clinical interpretation to the simple stated outcome: the drug failed to slow the disease in the reported test.
This Pharmalot column is a STAT+ piece, and parts of the coverage were behind a subscription wall at the time of publication. The public excerpt summarized the corporate split, inspection statistics, and Servier’s announcement. The article did not supply additional operational details on the CVS separation, such as management plans, spinoff mechanics, or regulatory filings. It also did not provide comprehensive FDA inspection counts, facility identities, or inspection results beyond the reported percentages for unannounced visits.
Readers with interest in the granular data—inspection logs, enforcement actions, or detailed trial data for the Servier compound—will need to consult the underlying regulatory sources, company disclosures, or the full STAT+ story. The public reporting closes on concrete items: CVS’s planned split slated for early 2028, the FDA’s increased share of unannounced inspections in India and China for FY 2026 (with the percentages reported), and Servier’s announcement that its purchased muscular dystrophy candidate failed its first major test. The article does not describe follow-up steps, ongoing studies, or regulatory reviews tied to these items.
Limitations and outstanding questions documented in the source include the absence of detailed operational or clinical data: the source did not report how CVS will allocate assets and liabilities between the two companies, whether the split requires additional approvals, which individual manufacturers or facilities the FDA inspected, or trial design parameters for Servier’s failed candidate. These gaps represent the explicit limits of the reported material and point to clear areas for further reporting and public disclosure.